Purchase this article with an account.
Kevin D. Lance, Samuel D. Good, Thaís S. Mendes, Mynna Ishikiriyama, Patrick Chew, Laurel S. Estes, Kazuhito Yamada, Sri Mudumba, Robert B. Bhisitkul, Tejal A. Desai; In Vitro and In Vivo Sustained Zero-Order Delivery of Rapamycin (Sirolimus) From a Biodegradable Intraocular Device. Invest. Ophthalmol. Vis. Sci. 2015;56(12):7331-7337. doi: 10.1167/iovs.15-17757.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
We created implantable intraocular devices capable of constant and continuous rapamycin release on the scale of months to years.
Polycaprolactone (PCL) thin films were used to encapsulate rapamycin to create implantable and biodegradable intraocular devices. Different film devices were studied by modifying the size, thickness, and porosity of the PCL films.
In vitro release of rapamycin was observed to be constant (zero-order) through 14 weeks of study. Release rates were tunable by altering PCL film porosity and thickness. In vivo release of rapamycin was observed out through 16 weeks with concentrations in the retina–choroid in the therapeutic range. Rapamycin concentration in the blood was below the lower limit of quantification. The drug remaining in the device was chemically stable in vitro and in vivo, and was sufficient to last for upwards of 2 years of total release. The mechanism of release is related to the dissolution kinetics of crystalline rapamycin.
Microporous PCL thin film devices demonstrate good ocular compatibility and the ability to release rapamycin locally to the eye over the course of many weeks.
This PDF is available to Subscribers Only